Latest revision as of 14:45, 14 October 2014

NRP UEA Norwich iGEM 2014

Safety Form

Your Training

a) Have your team members received any safety training yet?

Yes, we have already received safety training.

b) Please briefly describe the topics that you learned about (or will learn about) in your safety training.

c) Please give a link to the laboratory safety training requirements of your institution (college, university, community lab, etc). Or, if you cannot give a link, briefly describe the requirements.

Your Local Rules and Regulations

a) Who is responsible for biological safety at your institution? (You might have an Institutional Biosafety Committee, an Office of Environmental Health and Safety, a single Biosafety Officer, or some other arrangement.) Have you discussed your project with them? Describe any concerns they raised, and any changes you made in your project based on your discussion.

b) What are the biosafety guidelines of your institution? Please give a link to these guidelines, or briefly describe them if you cannot give a link.

c) In your country, what are the regulations that govern biosafety in research laboratories? Please give a link to these regulations, or briefly describe them if you cannot give a link.

Risks of Your Project Now

Please describe risks of working with the biological materials (cells, organisms, DNA, etc.) that you are using in your project. If you are taking any safety precautions (even basic ones, like rubber gloves), that is because your work has some risks, however small. Therefore, please discuss possible risks and what you have done (or might do) to minimize them, instead of simply saying that there are no risks at all.

a) Risks to the safety and health of team members, or other people working in the lab:

b) Risks to the safety and health of the general public (if any biological materials escaped from your lab):

c) Risks to the environment (from waste disposal, or from materials escaping from your lab):

d) Risks to security through malicious mis-use by individuals, groups, or countries:

e) What measures are you taking to reduce these risks? (For example: safe lab practices, choices of which organisms to use.)

Good laboratory practice and implementation will minimise risks. This will include restricted access to authorised workers, ensuring that all areas are swabbed with a recommended disinfectant, no laboratory clothing allowed outside of the laboratory and all outdoor clothing will be stored in offices. All contaminated waste will be autoclaved.

To reduce DNA transmission to neighbouring plants, the genetically modified plants will be confined to the laboratory and will be autoclaved after use. Any experiments involving Agrobacterium tumefaciens in transient expression experiments in Nicotiana benthamiana will be conducted in plant growth rooms that provide the necessary level of containment for infiltrated plants. All plant material in these growth rooms (whether infiltrated or not) will ultimately be destroyed by autoclaving in accordance with our institutional safety requirements.     
 
The strains of E.coli used are not known to be pathogenic and are laboratory strains that have less chance of surviving in the environment than naturally occurring, wild-type strains.

Risks of Your Project in the Future

What would happen if all your dreams came true, and your project grew from a small lab study into a commercial/industrial/medical product that was used by many people? We invite you to speculate broadly and discuss possibilities, rather than providing definite answers. Even if the product is "safe", please discuss possible risks and how they could be addressed, rather than simply saying that there are no risks at all.

a) What new risks might arise from your project's growth? (Consider the categories of risk listed in parts a-d of the previous question: lab workers, the general public, the environment, and malicious mis-uses.) Also, what risks might arise if the knowledge you generate or the methods you develop became widely available?

b) Does your project currently include any design features to reduce risks? Or, if you did all the future work to make your project grow into a popular product, would you plan to design any new features to minimize risks? (For example: auxotrophic chassis, physical containment, etc.) Such features are not required for an iGEM project, but many teams choose to explore them.

Further Comments

If you are completing a Preliminary Version of your Safety Form, use this space to describe how far you have progressed in your project, and give some comments about any questions that you left blank.

@@ Line 17: / Line 17: @@
      <link href="//maxcdn.bootstrapcdn.com/font-awesome/4.1.0/css/font-awesome.min.css" rel="stylesheet">
      <style type="text/css">
-       body{font-family:'Open Sans',sans-serif;font-size:13px}header{box-shadow:0 6px 6px rgba(0,0,0,.3)}header .container{height:80px}header .logo{padding:10px 0 10px 80px}header .igem{position:absolute;top:20px;right:-50px;z-index:100}header .igem img{width:40px;height:40px}header ul{float:right;list-style:none}header ul li{display:inline-block;white-space:nowrap}header ul li a{display:block;padding:0 15px;height:80px;line-height:80px;color:#000;text-decoration:none!important;transition:background-color .2s linear}header ul li a:active,header ul li a:hover,header ul li a:visited{background-color:#ecffeb;text-decoration:none!important;color:#000}header ul.dropdown-menu li{display:block}header ul.dropdown-menu li a{height:auto;padding:6px 20px;text-decoration:none}section{padding:50px 0}section h1{font-weight:300;font-size:48px;padding:0 0 50px}.dropdown-menu{margin:0}ul.menu li.dropdown:hover>ul.dropdown-menu{display:block}.bx-wrapper img{display:block;max-width:100%;min-width:970px;margin:0 auto}.welcome{padding:80px 0;background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.about{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.about h2{font-size:18px;font-weight:700}.about p.project{font-size:14px;padding:10px}.about p.project:last-of-type{padding-bottom:40px}.about .row:first-of-type{margin-bottom:40px}.about .col-md-4 i{transition:color .2s linear}.about .col-md-4:hover i{color:#2ECC71}.team{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png);transition:all .3s linear;padding:0 0 40px}.team .img-responsive{border-radius:20em;-webkit-border-radius:20em;-moz-border-radius:20em;-webkit-filter:grayscale(100%);-moz-filter:grayscale(100%);-ms-filter:grayscale(100%);filter:grayscale(100%);filter:gray;transition:all .3s linear;max-width:200px;margin:0 auto}.team .col-md-4:hover .img-responsive{-webkit-filter:none;-moz-filter:none;-ms-filter:none;filter:none}.team .row:first-of-type{margin-bottom:40px}.team h2{font-size:18px;font-weight:700;color:#019875}.team h3{font-size:13px;font-weight:700;color:#019875}.team .col-md-3{padding:0 30px}.team .meetourteam{margin-bottom:60px}.social{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.sponsors .col-md-2{display:table;height:90px}.sponsors .middle{display:table-cell;vertical-align:middle}.sponsors .row:first-of-type{margin-bottom:40px}.general{padding-top:0;background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.title{background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.title h1,.title h2{text-align:center}.title h1{margin-top:0;padding:40px 0;margin-bottom:40px}.title h2{font-size:18px;color:#999;margin:0 0 50px;padding-bottom:40px}.general p{margin:0 0 40px}.fa-8x{font-size:8em;color:#019875}.row .boxed-headline{width:100%;height:200px;background-color:#90C695}.container .overview{padding-bottom:40px}footer{color:#444;background-color:#F2F1EF;padding:50px 0}footer ul.sponsors{float:left;width:100%;padding:0;margin:20px 0 0;list-style-type:none}footer ul.sponsors li{display:inline;padding:0 20px}footer ul.sponsors li img{width:90px}#top-section{border:0;height:14px;z-index:100;top:0;position:fixed;width:975px;left:50%;margin-left:-487px;background-color:transparent}#content,#globalWrapper{width:100%;height:100%;border:0;background-color:transparent;margin:0;padding:0;font-size:100%}#catlinks,#contentSub,#footer-box,#p-logo,#search-controls,#sitesub,.firstHeading,.printfooter,.visualClear{display:none}h1,h2,h3,h4,h5,h6{border-bottom:none}#bodyContent h1,#bodyContent h2{margin-bottom:40px}
+       body{font-family:'Open Sans',sans-serif;font-size:13px}header{box-shadow:0 6px 6px rgba(0,0,0,.3)}header .container{height:80px}header .logo{padding:10px 0 10px 80px}header .igem{position:absolute;top:20px;right:-50px;z-index:100}header .igem img{width:40px;height:40px}header ul{float:right;list-style:none}header ul li{display:inline-block;white-space:nowrap}header ul li a{display:block;padding:0 15px;height:80px;line-height:80px;color:#000;text-decoration:none!important;transition:background-color .2s linear}header ul li a:active,header ul li a:hover,header ul li a:visited{background-color:#ecffeb;text-decoration:none!important;color:#000}header ul.dropdown-menu li{display:block}header ul.dropdown-menu li a{height:auto;padding:6px 20px;text-decoration:none}section{padding:50px 0}section h1{font-weight:300;font-size:48px;padding:0 0 50px}.dropdown-menu{margin:0}ul.menu li.dropdown:hover>ul.dropdown-menu{display:block}.bx-wrapper img{display:block;max-width:100%;min-width:970px;margin:0 auto}.welcome{padding:80px 0;background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.about{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.about h2{font-size:18px;font-weight:700}.about p.project{font-size:14px;padding:10px}.about p.project:last-of-type{padding-bottom:40px}.about .row:first-of-type{margin-bottom:40px}.about .col-md-4 i{transition:color .2s linear}.about .col-md-4:hover i{color:#2ECC71}.team{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png);transition:all .3s linear;padding:0 0 40px}.team .img-responsive{border-radius:20em;-webkit-border-radius:20em;-moz-border-radius:20em;-webkit-filter:grayscale(100%);-moz-filter:grayscale(100%);-ms-filter:grayscale(100%);filter:grayscale(100%);filter:gray;transition:all .3s linear;max-width:200px;margin:0 auto}.team .col-md-4:hover .img-responsive{-webkit-filter:none;-moz-filter:none;-ms-filter:none;filter:none}.team .row:first-of-type{margin-bottom:40px}.team h2{font-size:18px;font-weight:700;color:#019875}.team h3{font-size:13px;font-weight:700;color:#019875}.team .col-md-3{padding:0 30px}.team .meetourteam{margin-bottom:60px}.social{background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.sponsors .col-md-2{display:table;height:90px}.sponsors .middle{display:table-cell;vertical-align:middle}.sponsors .row:first-of-type{margin-bottom:40px}.general{padding-top:0;background:url(https://static.igem.org/mediawiki/2014/d/d7/Uea_body-bg.png)}.title{background:url(https://static.igem.org/mediawiki/2014/0/06/Uea_header-bg.png)}.title h1,.title h2{text-align:center}.title h1{margin-top:0;padding:40px 0;margin-bottom:40px}.title h2{font-size:18px;color:#999;margin:0 0 50px;padding-bottom:40px}.general p{margin:0 0 40px}.fa-8x{font-size:8em;color:#019875}.row .boxed-headline{width:100%;height:200px;background-color:#90C695}.container .overview{padding-bottom:40px}footer{color:#444;background-color:#FFFFF;padding:50px 0}footer ul.sponsors{float:left;width:100%;padding:0;margin:20px 0 0;list-style-type:none}footer ul.sponsors li{display:inline;padding:0 20px}footer ul.sponsors li img{width:90px}#top-section{border:0;height:14px;z-index:100;top:0;position:fixed;width:975px;left:50%;margin-left:-487px;background-color:transparent}#content,#globalWrapper{width:100%;height:100%;border:0;background-color:transparent;margin:0;padding:0;font-size:100%}#catlinks,#contentSub,#footer-box,#p-logo,#search-controls,#sitesub,.firstHeading,.printfooter,.visualClear{display:none}h1,h2,h3,h4,h5,h6{border-bottom:none}#bodyContent h1,#bodyContent h2{margin-bottom:40px}
      </style>
    </head>
@@ Line 33: / Line 33: @@
          <div class="row">
            <div class="col-md-2">
-            <img src="https://static.igem.org/mediawiki/2014/e/e0/Uea_logo.png" class="logo"/>
+           <a href="https://2014.igem.org/Team:NRP-UEA-Norwich"/><img src="https://static.igem.org/mediawiki/2014/e/e0/Uea_logo.png" class="logo"/></a>
              <div class="igem">
-               <a href="https://2014.igem.org/Main_Page"/><img src="https://static.igem.org/mediawiki/2014/a/a3/Uea_igem-logo.png"/></a>
+               <a href="https://2014.igem.org/Main_Page"/ target="_blank"><img src="https://static.igem.org/mediawiki/2014/a/a3/Uea_igem-logo.png"/></a>
              </div>
            </div>
@@ Line 59: / Line 59: @@
                    <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Project_Mo-Flipper">Golden Gate Modular Flipper</a></li>
                    <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/HP_Collaborations">Collaborations</a></li>
+                  <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Judging_Criteria">Judging Criteria</a></li>
                  </ul>
                </li>
@@ Line 81: / Line 82: @@
                  <a data-toggle="dropdown" class="dropdown-toggle" href="#">Safety <span class="caret"></span></a>
                  <ul class="dropdown-menu">
+                  <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety">Safety Overview</a></li>
                    <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_Forms">Safety Forms</a></li>
                    <li><a href="https://2014.igem.org/Team:NRP-UEA-Norwich/Safety_RA">Risk Assessments</a></li>
@@ Line 190: / Line 192: @@
 <p class="qbody"><span class="qnum">e)</span> What measures are you taking to reduce these risks? (For example: safe lab practices, choices of which organisms to use.)</p>
-<textarea cols="100" rows="8" id="reduce_risks_now" data-form-field="reduce_risks_now">Good laboratory practice and implementation will minimise risks. This will include restricted access to authorised workers, ensuring that all areas are swabbed with a recommended disinfectant, no laboratory clothing allowed outside of the laboratory and all outdoor clothing will be stored in offices. All contaminated waste will be autoclaved.
+<textarea cols="100" rows="9" id="reduce_risks_now" data-form-field="reduce_risks_now">Good laboratory practice and implementation will minimise risks. This will include restricted access to authorised workers, ensuring that all areas are swabbed with a recommended disinfectant, no laboratory clothing allowed outside of the laboratory and all outdoor clothing will be stored in offices. All contaminated waste will be autoclaved.
 To reduce DNA transmission to neighbouring plants, the genetically modified plants will be confined to the laboratory and will be autoclaved after use. Any experiments involving Agrobacterium tumefaciens in transient expression experiments in Nicotiana benthamiana will be conducted in plant growth rooms that provide the necessary level of containment for infiltrated plants. All plant material in these growth rooms (whether infiltrated or not) will ultimately be destroyed by autoclaving in accordance with our institutional safety requirements.
@@ Line 231: / Line 233: @@
        </div>
        <div class="container">
+      </div>
+    </section>
        </div>
@@ Line 249: / Line 254: @@
              <li><img src="https://static.igem.org/mediawiki/2014/1/13/Uea_tsl.png"/></li>
              <li><img src="https://static.igem.org/mediawiki/2014/0/0f/Uea_uea.png"/></li>
+            <li><img src="https://static.igem.org/mediawiki/2014/f/f2/Uea_eppendorf.png"/></li>
              <li><img src="https://static.igem.org/mediawiki/2014/3/36/Uea_welcometrust.png"/></li>
+            <li><img src="https://static.igem.org/mediawiki/2014/c/c7/Uea_john-innes-centre.png"/></li>
+            <li><img src="https://static.igem.org/mediawiki/2014/a/a3/Uea_transglobal.png"/></li>
            </ul>
          </div>

Team:NRP-UEA-Norwich/Safety Forms

From 2014.igem.org

Latest revision as of 14:45, 14 October 2014

Safety Form